|
|
|
|
|
|
| Protocol | Study Chair |
Information for Patients and Families |
Information for Health Professionals |
|---|---|---|---|
|
PBTC-026: A Feasibility Study of SAHA combined with Isotretinoin and Chemotherapy in Infants with Embryonal Tumors of the Central Nervous System |
J. Russell Geyer, MD Seattle Children's Hospital Seattle, WA. Phone: (206) 987-6664 Email: russ.geyer@seattlechildrens.org |
Summary for Patients and Families | Abstract for Health Professionals |
|
PBTC-029: Phase I and Pharmacokinetic Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma |
Anu Banerjee, MD University of California San Francisco (UCSF) San Francisco, CA. Phone: (415) 476-3831 Email: banerjee@neurosurg.ucsf.edu |
Summary for Patients and Families | Abstract for Health Professionals |
|
PBTC-032: A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Children with Recurrent or Refractory Medulloblastoma |
Amar J. Gajjar, MD St Jude Children's Research Hospital Memphis, TN. Phone: (901) 595-4599 Email: amar.gajjar@stjude.org |
Summary for Patients and Families | Abstract for Health Professionals |
|
PBTC-033: A Phase I/ II Study of ABT-888, an Oral Poly(ADP-ribose) Polymerase Inhibitor, and Concurrent Radiation Therapy, Followed by ABT-888 and Temozolomide, in Children with Newly Diagnosed Diffuse Pontine Gliomas (DIPG) |
Patricia A. Baxter, M.D Texas Children's Cancer Center Houston TX Phone: (832) 824-4681 Email: pabaxter@txch.org |
Summary for Patients and Families | Abstract for Health Professionals |
|
PBTC-036: A Molecular Biology and Phase II Study of Imetelstat (GRN163L) in Children with Recurrent High-Grade Glioma, Ependymoma, Medulloblastoma/Primitive Neuroectodermal Tumor and Diffuse Intrinsic Pontine Glioma |
Maryam Fouladi, M.D Cincinnati Children's Hospital Medical Center Cincinnati, OH Phone: (513) 803-0721 Email: maryam.fouladi@cchmc.org |
Summary for Patients and Families | Abstract for Health Professionals |
PBTC
Closed Protocol Summaries
| Protocol | Study Chair |
Information for Health Professionals |
|---|---|---|
|
PBTC-001:
Pilot Study of Systemic and Intrathecal Chemotherapy followed by Conformal Radiation for Infants with Embryonal Intracranial Central Nervous System Tumors |
Susan Blaney, MD Texas Children's Research Hospital Houston, TX. Phone: (832) 822-4586 Email: sblaney@txccc.org |
Abstract for Health Professionals |
|
PBTC-002: A Phase I Study of SU5416 in Pediatric Patients With Recurrent or Progressive Poor Prognosis Brain Tumors |
Mark W. Kieran, MD, PhD Dana-Farber Cancer Institute Boston, MA. Phone: (617) 632-4907 Email: mark_kieran@dfci.harvard.edu |
Abstract for Health Professionals |
|
PBTC-003:
Phase I Trial of Escalating Oral Doses of SCH 66336 in Pediatric Patients with Refractory or Recurrent Brain Tumors |
Mark W. Kieran, MD, PhD Dana-Farber Cancer Institute Boston, MA. Phone: (617) 632-4907 Email: mark_kieran@dfci.harvard.edu |
Abstract for Health Professionals |
|
PBTC-004: Phase I Study of Intrathecal SpartajectTM-Busulfan in Children with Neoplastic Meningitis |
Sri Gururangan, MRCP (UK) Duke University Medical Center Durham, NC. Phone: (919) 668-6288 Email: gurur002@mc.duke.edu |
Abstract for Health Professionals |
|
PBTC-005: Phase I Trial of Temozolomide and O6-Benzylguanine in Pediatric Patients with Recurrent Brain Tumors |
Amar J. Gajjar, MD St Jude Children's Research Hospital Memphis, TN. Phone: (901) 595-3604 Email: amar.gajjar@stjude.org |
Abstract for Health Professionals |
|
PBTC-006: A Phase I/II Trial of STI571 in Children with Newly Diagnosed Poor Prognosis Brainstem Gliomas and Recurrent Intracranial Malignant Gliomas |
Ian F. Pollack, MD Children's Hospital of Pittsburgh Pittsburgh, PA. Phone: (412) 692-5881 Email: ian.pollack@chp.edu |
Abstract for Health Professionals |
|
PBTC-007: A Phase I/II Trial of ZD1839 (IressaTM) and Radiation in Pediatric Patients Newly Diagnosed with Brain Stem Tumors or Incompletely Resected Supratentorial Malignant Gliomas with Phase II limited to Brain Stem Tumors |
J. Russell Geyer, MD Seattle Children's Hospital Seattle, WA. Phone: (206) 987-6664 Email: russ.geyer@seattlechildrens.org |
Abstract for Health Professionals |
|
PBTC-009: Phase I Trial of GLIADEL® and O6-Benzylguanine in Pediatric Patients with Recurrent Malignant Gliomas |
Ian F. Pollack, MD Children's Hospital of Pittsburgh Pittsburgh, PA. Phone: (412) 692-5881 Email: ian.pollack@chp.edu |
Abstract for Health Professionals |
|
PBTC-010: A Phase II Study of Oxaliplatin in Children with Recurrent or Refractory Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumors and Atypical Teratoid Rhabdoid Tumors |
Maryam Fouladi, MD St Jude Children's Research Hospital Memphis, TN. Phone: (901) 595-2094 Email: maryam.fouladi@stjude.org |
Abstract for Health Professionals |
|
PBTC-011C: Phase I/II Trial of Intracerebral IL13-PE38QQR Infusion in Pediatric Patients with Recurrent Malignant Glioma |
Anuradha Banerjee, MD, MPH University of California, San Francisco San Francisco, CA. Phone: (415) 353-2966 Email: Banerjee@neurosurg.ucsf.edu |
Abstract for Health Professionals |
|
PBTC-012: Phase I Study of Cilengitide (EMD 121974) in Children with Refractory Brain Tumors |
Tobey MacDonald, MD Children's National Medical Center Washington, DC. Phone: (202) 884-2146 Email: tmacdona@cnmc.org |
Abstract for Health Professionals |
|
PBTC-013: A Phase I/II Study of a Recombinant Chimeric Protein Composed of Transforming Growth Factor (TGF)-a and a Mutated Form of the Pseudomonas Exotoxin Termed PE38 (TP-38) in Pediatric Patients with Recurrent or Progressive Supratentorial High Grade Gliomas |
Roger Packer, MD Children's National Medical Center Washington, DC. Phone: (202) 884-2120 Email: rpacker@cnmc.org |
Abstract for Health Professionals |
|
PBTC-014: Phase I/II Trial of Zarnestra and XRT in Pediatric Patients with Newly Diagnosed Non-Disseminated Intrinsic Diffuse Brainstem Gliomas |
Daphne Haas-Kogan, MD University of California, San Francisco San Francisco, CA. Phone: (415) 353-7175 Email: hkogan@radonc17.ucsf.edu |
Abstract for Health Professionals |
|
PBTC-015: A Phase II Trial of O6-Benzylguanine and Temozolomide in Pediatric Patients with Recurrent or Progressive High-Grade Gliomas and Recurrent or Progressive Brainstem Tumors |
Kathy Warren, MD National Cancer Institute Pediatric-Oncology Branch Bethesda, MD. Phone: (301) 402-6298 Email: warrenk@mail.nih.gov |
Abstract for Health Professionals |
|
PBTC-016:
A Phase I, Molecular Biology and Phase II Study of Lapatinib (GW572016) in Pediatric Patients with Recurrent or Refractory Medulloblastoma, Malignant Glioma or Ependymoma |
Maryam Fouladi, MD St Jude Children's Research Hospital Memphis, TN. Phone: (901) 595-2094 Email: maryam.fouladi@stjude.org |
Abstract for Health Professionals |
|
PBTC-017:
Phase I Study of CLORETAZINE ™ (VNP4010M) in Children with Recurrent, Progressive or Refractory Primary Brain Tumors |
Sri Gururangan, MRCP (UK) Duke University Medical Center Durham, NC. Phone: (919) 668-6288 Email: gurur002@mc.duke.edu |
Abstract for Health Professionals |
|
PBTC-018:
A Phase I Trial of CC-5013 (Lenalidomide) in Pediatric Patients with Recurrent or Refractory Primary CNS Tumors |
Kathy Warren, MD National Cancer Institute Pediatric-Oncology Branch Bethesda, MD. Phone: (301) 402-6298 Email: warrenk@mail.nih.gov |
Abstract for Health Professionals |
|
PBTC-019:
A Phase I Pharmacokinetic Optimal Dosing Study of Intrathecal Topotecan for Children with Neoplastic Meningitis |
Susan Blaney, MD Texas Children's Research Hospital Houston, TX. Phone: (832) 822-4586 Email: sblaney@txccc.org |
Abstract for Health Professionals |
|
PBTC-020:
A Phase I Clinical Trial of AZD2171 in Children with Recurrent or Progressive Central Nervous System (CNS) Tumors |
Mark Kieran, MD, PhD Dana-Farber Cancer Institute Boston, MA. Phone: (617) 632-4907 Email: mark_kieran@dfci.harvard.edu |
Abstract for Health Professionals |
|
PBTC-021:
A Phase I Trial of Capecitabine Rapidly Disintegrating Tablets and Concomitant Radiation Therapy in Children with Newly Diagnosed Brainstem Gliomas and High Grade Gliomas |
Susan Blaney, MD Texas Children's Research Hospital Houston, TX. Phone: (832) 822-4586 Email: sblaney@txccc.org |
Abstract for Health Professionals |
|
PBTC-022:
Phase II study of Bevacizumab plus Irinotecan (CamptosarTM) in Children with Recurrent, Progressive, or Refractory Malignant Gliomas, Diffuse/Intrinsic Brain Stem Gliomas, Medulloblastomas, Ependymomas and Low Grade Gliomas |
Sri Gururangan, MRCP (UK) Duke University Medical Center Durham, NC. Phone: (919) 668-6288 Email: gurur002@mc.duke.edu |
Abstract for Health Professionals |
|
PBTC-023: Phase I and Pharmacokinetic Study of Enzastaurin (LY317615) in Children and Adolescents with Refractory Primary CNS Tumors |
Susan Blaney, MD Texas Children's Research Hospital Houston, TX. Phone: (832) 822-4586 Email: sblaney@txccc.org |
Abstract for Health Professionals |
|
PBTC-024: A Phase I Study of MK-0752 in Pediatric Patients with Recurrent or Refractory CNS Malignancies |
Maryam Fouladi, MD Cincinnati Children's Hospital Medical Center, Cincinnati, OH. Phone: (513) 636-4266 Email: maryam.fouladi@cchmc.org |
Abstract for Health Professionals |
|
PBTC-025: A Phase I Pharmacokinetic and Safety Study in Children with Recurrent or Refractory Medulloblastoma to Identify a Pharmacokinetic Based Dose for GDC-0449 |
Amar J. Gajjar, MD St Jude Children's Research Hospital Memphis, TN. Phone: (901) 595-4599 Email: amar.gajjar@stjude.org |
Abstract for Health Professionals |
|
PBTC-025B: A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Adults with Recurrent or Refractory Medulloblastoma |
Amar J. Gajjar, MD St Jude Children's Research Hospital Memphis, TN. Phone: (901) 595-4599 Email: amar.gajjar@stjude.org |
Abstract for Health Professionals |
|
PBTC-027: A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children with Recurrent/Refractory CNS Tumors |
Jack Su, MD Texas Children's Research Hospital Houston, TX. Phone: (832) 822-4306 Email: jmsu@txccc.org |
Abstract for Health Professionals |
|
PBTC-030: A Phase II Trial of Capecitabine Rapidly Disintegrating Tablets and Concomitant Radiation Therapy in Children with Newly Diagnosed Brainstem Gliomas |
Lindsay Kilburn, MD Children's National Medical Center Washington, DC. Phone: (202) 476-2800 Email: LKilburn@childrensnational.org |
Abstract for Health Professionals |
|
PBTC-031: Phase I and Pharmacokinetic Trial of PTC299 in Pediatric Patients with Refractory or Recurrent CNS Tumors |
Roger Packer, MD Children's National Medical Center Washington, DC. Phone: (202) 476-5973 Email: rpacker@cnmc.org |
Abstract for Health Professionals |
|
|
|
|
|
|
|
|
|
|
|
|
